Haematologica, Vol 93, Issue 2, 295-298 doi:10.3324/haematol.11627
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wechalekar, A. D.
Right arrow Articles by Gillmore, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wechalekar, A. D.
Right arrow Articles by Gillmore, J. D.

Amyloidosis

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease

Ashutosh D. Wechalekar, Helen J. Lachmann, Mark Offer, Philip N. Hawkins, Julian D. Gillmore

National Amyloidosis Centre, Centre for Amyloidosis & Acute Phase Proteins, Department of Medicine (Hampstead Campus), Royal Free and University College Medical School, London, United Kingdom

Correspondence: Ashutosh Wechalekar, National Amyloidosis Centre, Department of Medicine, Royal Free and University College Medical School, Rowland Hill St, London NW3 2PF, United Kingdom. E-mail: a.wechalekar{at}medsch.ucl.ac.uk

We report preliminary observations on the efficacy of bortezomib in 20 patients with AL amyloidosis whose clonal disease was active despite treatment with a median of 3 lines of prior chemotherapy, including a thalidomide combination in all cases. Patients received a median of 3 (range 1–6) cycles of bortezomib and 9 (45%) patients received concurrent dexamethasone. Three (15%) patients achieved complete hematologic responses, and a further 13 (65%) achieved partial responses. Fifteen (75%) patients experienced some degree of toxicity, which in 8 (40%) cases resulted in discontinuation of bortezomib. Bortezomib shows promise in the treatment of systemic AL amyloidosis.

Key words: amyloidosis, bortezomib, chemotherapy..




This article has been cited by other articles:


Home page
BloodHome page
D. E. Reece, V. Sanchorawala, U. Hegenbart, G. Merlini, G. Palladini, J.-P. Fermand, R. A. Vescio, X. Liu, Y. A. Elsayed, A. Cakana, et al.
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
Blood, August 20, 2009; 114(8): 1489 - 1497.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
G. Palladini and G. Merlini
Current treatment of AL amyloidosis
Haematologica, August 1, 2009; 94(8): 1044 - 1048.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
L. M. Dember
Modern Treatment of Amyloidosis: Unresolved Questions
J. Am. Soc. Nephrol., March 1, 2009; 20(3): 469 - 472.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Solomon, S. D. Macy, C. Wooliver, D. T. Weiss, and P. Westermark
Splenic plasma cells can serve as a source of amyloidogenic light chains
Blood, February 12, 2009; 113(7): 1501 - 1503.
[Abstract] [Full Text] [PDF]